Westminster Irbesartan Tablets, USP 75 mg Rx Only Manufactured by: ScieGen Pharmaceuticals, Inc. ...
FDA Drug Recall #D-0300-2019 — Class II — October 29, 2018
Recall Summary
| Recall Number | D-0300-2019 |
| Classification | Class II — Moderate risk |
| Date Initiated | October 29, 2018 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Westminster Pharmaceuticals Llc |
| Location | Olive Branch, MS |
| Product Type | Drugs |
| Quantity | 1571 bottles |
Product Description
Westminster Irbesartan Tablets, USP 75 mg Rx Only Manufactured by: ScieGen Pharmaceuticals, Inc. Hauppauge, NY 11788 Manufactured for: Westminster Pharmaceuticals, LLC. Olive Branch, MS 38654 a) 30 count bottle NDC 69367-119-01; b) 90 count bottle NDC 69367-119-03
Reason for Recall
CGMP Deviations: FDA laboratory testing confirmed traces of NDEA impurity in specific lots of Irbesartan.
Distribution Pattern
Nationwide.
Lot / Code Information
Batch Numbers: a) B160002A Exp. 09/30/2019; b) B160002B Exp. 09/30/2019
Other Recalls from Westminster Pharmaceuticals Llc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0582-2025 | Class II | Metoprolol Tartrate Tablets, USP, 100 mg, 1000 ... | Aug 6, 2025 |
| D-0581-2025 | Class II | Metoprolol Tartrate Tablets, USP, 50 mg, 1000 T... | Aug 6, 2025 |
| D-0302-2019 | Class II | Westminster Irbesartan Tablets, USP 300 mg Rx O... | Oct 29, 2018 |
| D-0301-2019 | Class II | Westminster Irbesartan Tablets, USP 150 mg Rx O... | Oct 29, 2018 |
| D-1178-2018 | Class I | Levothyroxine and Liothyronine (Thyroid Tablets... | Aug 3, 2018 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.